Glaxo Agrees to Pay $3 Billion in Fraud Settlement


In the largest settlement involving a pharmaceutical company, the British drugmaker agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday. The agreement also includes civil penalties for improper marketing of a half-dozen other drugs.




The fine against GlaxoSmithKline over , Wellbutrin, and the other drugs makes this year a record for money recovered by the federal government under its so-called whistle-blower law, according to a group that tracks such numbers.

Read the full story:

Source: The New York Times